Pub Date : 2026-02-18DOI: 10.1093/eurheartj/ehaf784.3900
B S Prado, A Franci, L Baracioli, K Razimavicius, R Saretta, R Kalil-Filho, L F Drager
Background Obesity is the main risk factor for Obstructive Sleep Apnoea (OSA). Previous studies have shown that OSA affects ~50-70% of patients with obesity and exacerbates sympathetic activation, inflammation and endothelial dysfunction in these patients. However, it is still unclear whether OSA exacerbates cardiovascular (CV) events in patients with obesity. Purpose To test the hypothesis that OSA increases CV events in patients with obesity regardless of its grade. Methods We conducted a retrospective cohort analysis using the TriNetX Global Health Research Network through anonymised electronic medical records. We identified adult patients >40 years with obesity without previous anti-obesity therapy (GLP-1 agonists and tirzepatide) or bariatric surgery. We excluded patients with previous episodes of myocardial infarction and/or stroke. We used multiple code recommendations for tracking the presence of OSA, according to the international Classification of Diseases 10th edition: G47.33, G47.3, G47.39 or G47.30. We performed a propensity score matching in a 1:1 ratio for age, sex, ethnicity, hypertension, diabetes, dyslipidemia, smoking and chronic kidney disease. The combined endpoint included the incidence of 3-point MACE (non-fatal myocardial infarction, non-fatal stroke and all-cause mortality). Results In a crude analysis, patients with obesity+OSA represented approximately 15% of the sample. After the propensity score matching, 1,534,850 patients with obesity were included for the analysis (50% in each group: with and without OSA). After a median of 730 days of follow-up, OSA increased the incidence of combined events by 11% (OR:1.11; 95% CI: 1.09 – 1.13). A stratified analysis by different grades of obesity revealed that this result was driven by more severe classes of obesity: grade 1 (OR: 0.92; 95% CI: 0.85 – 1.00), grade 2 (OR: 1.06; 95% CI: 0.98 –1.17) and grade 3 (OR:1.08; 95% CI: 1.04 – 1.13). Conclusion OSA is associated with a modest increase in the incidence of MACE in patients with obesity. These results are probably attenuated by not capturing potential OSA underdiagnosis and OSA treatment in patients with obesity. Increasing OSA awareness in patients with obesity may be an interesting strategy for decreasing the cardiovascular burden associated with obesity in parallel to the improvement of sleep-related symptoms in these patients.
{"title":"Is obstructive sleep apnoea more than an epiphenomenon in patients with obesity? A cardiovascular perspective from a real-world propensity score-matched study","authors":"B S Prado, A Franci, L Baracioli, K Razimavicius, R Saretta, R Kalil-Filho, L F Drager","doi":"10.1093/eurheartj/ehaf784.3900","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf784.3900","url":null,"abstract":"Background Obesity is the main risk factor for Obstructive Sleep Apnoea (OSA). Previous studies have shown that OSA affects ~50-70% of patients with obesity and exacerbates sympathetic activation, inflammation and endothelial dysfunction in these patients. However, it is still unclear whether OSA exacerbates cardiovascular (CV) events in patients with obesity. Purpose To test the hypothesis that OSA increases CV events in patients with obesity regardless of its grade. Methods We conducted a retrospective cohort analysis using the TriNetX Global Health Research Network through anonymised electronic medical records. We identified adult patients >40 years with obesity without previous anti-obesity therapy (GLP-1 agonists and tirzepatide) or bariatric surgery. We excluded patients with previous episodes of myocardial infarction and/or stroke. We used multiple code recommendations for tracking the presence of OSA, according to the international Classification of Diseases 10th edition: G47.33, G47.3, G47.39 or G47.30. We performed a propensity score matching in a 1:1 ratio for age, sex, ethnicity, hypertension, diabetes, dyslipidemia, smoking and chronic kidney disease. The combined endpoint included the incidence of 3-point MACE (non-fatal myocardial infarction, non-fatal stroke and all-cause mortality). Results In a crude analysis, patients with obesity+OSA represented approximately 15% of the sample. After the propensity score matching, 1,534,850 patients with obesity were included for the analysis (50% in each group: with and without OSA). After a median of 730 days of follow-up, OSA increased the incidence of combined events by 11% (OR:1.11; 95% CI: 1.09 – 1.13). A stratified analysis by different grades of obesity revealed that this result was driven by more severe classes of obesity: grade 1 (OR: 0.92; 95% CI: 0.85 – 1.00), grade 2 (OR: 1.06; 95% CI: 0.98 –1.17) and grade 3 (OR:1.08; 95% CI: 1.04 – 1.13). Conclusion OSA is associated with a modest increase in the incidence of MACE in patients with obesity. These results are probably attenuated by not capturing potential OSA underdiagnosis and OSA treatment in patients with obesity. Increasing OSA awareness in patients with obesity may be an interesting strategy for decreasing the cardiovascular burden associated with obesity in parallel to the improvement of sleep-related symptoms in these patients.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"30 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2026-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146210308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-18DOI: 10.1093/eurheartj/ehag066
Sicheng Li, Wei Wang, Hanwen Zhou, Yuqin Zhang, Lin Chen, Jiyi Lin, Nawsherwan, Yong Huo, Junbo Ge, Bin Wang, Yan Wang
Background and aims: Evidence on the associations between tropical cyclone (TC) exposure and acute coronary syndrome (ACS) remains limited, particularly in developing countries. Therefore, this study aimed to investigate the short-term association between TC exposure and ACS incidence and explore potential effect modifiers.
Methods: This time-stratified case-crossover study included ACS patients from a nationwide registry in mainland China between 2015 and 2022. The Willoughby wind field model was chosen to estimate TC-associated wind speeds, with TC exposure defined as the occurrence of daily maximum sustained wind speeds ≥17.5 m/s. The outcomes included ACS and its subtypes, namely, ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. Conditional quasi-Poisson models with distributed lag non-linear models were applied to assess TC-ACS associations and lag structures. Subgroup analyses were conducted to identify potential effect modifiers.
Results: A total of 2 563 780 individuals (64.0 ± 12.4 years; 68% males) were included. Compared with non-TC days, TC days were associated with longer delays in self-referral to the hospital (5.8 vs 5.3 h) and longer admission-to-catheterization times (1.0 vs 0.9 h). Over the 0-3-day period following TC exposure, the risk of developing ACS increased by 14% (95% confidence interval: 2% to 27%). Stronger associations were observed among males, individuals with lower education levels, and those with more ACS risk factors.
Conclusions: TC exposure may increase the ACS burden by simultaneously increasing the risk of incidence and delaying treatment. The government, the public, and healthcare institutions must collaborate proactively to alleviate the burden of TC-associated ACS.
{"title":"Tropical cyclones and acute coronary syndromes: a Chinese nationwide study.","authors":"Sicheng Li, Wei Wang, Hanwen Zhou, Yuqin Zhang, Lin Chen, Jiyi Lin, Nawsherwan, Yong Huo, Junbo Ge, Bin Wang, Yan Wang","doi":"10.1093/eurheartj/ehag066","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag066","url":null,"abstract":"<p><strong>Background and aims: </strong>Evidence on the associations between tropical cyclone (TC) exposure and acute coronary syndrome (ACS) remains limited, particularly in developing countries. Therefore, this study aimed to investigate the short-term association between TC exposure and ACS incidence and explore potential effect modifiers.</p><p><strong>Methods: </strong>This time-stratified case-crossover study included ACS patients from a nationwide registry in mainland China between 2015 and 2022. The Willoughby wind field model was chosen to estimate TC-associated wind speeds, with TC exposure defined as the occurrence of daily maximum sustained wind speeds ≥17.5 m/s. The outcomes included ACS and its subtypes, namely, ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. Conditional quasi-Poisson models with distributed lag non-linear models were applied to assess TC-ACS associations and lag structures. Subgroup analyses were conducted to identify potential effect modifiers.</p><p><strong>Results: </strong>A total of 2 563 780 individuals (64.0 ± 12.4 years; 68% males) were included. Compared with non-TC days, TC days were associated with longer delays in self-referral to the hospital (5.8 vs 5.3 h) and longer admission-to-catheterization times (1.0 vs 0.9 h). Over the 0-3-day period following TC exposure, the risk of developing ACS increased by 14% (95% confidence interval: 2% to 27%). Stronger associations were observed among males, individuals with lower education levels, and those with more ACS risk factors.</p><p><strong>Conclusions: </strong>TC exposure may increase the ACS burden by simultaneously increasing the risk of incidence and delaying treatment. The government, the public, and healthcare institutions must collaborate proactively to alleviate the burden of TC-associated ACS.</p>","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":35.6,"publicationDate":"2026-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146219195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-18DOI: 10.1093/eurheartj/ehaf853
Gaurav Sharma, Piyush Tak
{"title":"AI-ECG for predicting regurgitant valve disease: a promising advance in need of clinical anchoring.","authors":"Gaurav Sharma, Piyush Tak","doi":"10.1093/eurheartj/ehaf853","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf853","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":35.6,"publicationDate":"2026-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146219147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-18DOI: 10.1093/eurheartj/ehag031
Robin Le Ruz, Michael Brener, Karl Philip Rommel
{"title":"Acute haemodynamic instability after transcatheter tricuspid valve replacement: insights from pressure-volume loops.","authors":"Robin Le Ruz, Michael Brener, Karl Philip Rommel","doi":"10.1093/eurheartj/ehag031","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag031","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":35.6,"publicationDate":"2026-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146219175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-18DOI: 10.1093/eurheartj/ehaf784.2813
G Albenque, C Batteux, C Karsenty, I Bouzguenda, P Aldebert, J Radojevic, G Bosser, B Lefort, P Moceri, R N Haddad, H Bouvaist, N Combes, A Houeijeh, V Ciobotaru, S Hascoet
Transcatheter correction has been a new innovative treatment for superior sinus venosus defects (SVDs). A dedicated long partially covered XXL stent has been developed specifically for this procedure. Its safety and efficacy have to be investigated. This study aims to evaluate the efficacy and safety of transcatheter SVDs correction with the OTIMUS XXL® partially covered stent. A prospective, nationwide, multi-center cohort study with approval to include 60 consecutive patients started in June 2023. Preliminary early and mid-term (6 months) outcomes were collected. Results: Thirty adults were enrolled over one year in 5 centers (mean age 61 years; female, 73%; dyspnea, 90%; history of atrial arrhythmia, 43%; pulmonary hypertension, 40%; heart failure, 47%; mean indexed right ventricular end-telediastolic volume= 140mL/m² on MRI). Simulation of transcatheter SVD closure was done virtually and on 3D printed models in all cases. All procedures were successful. Pulmonary vein pathway was protected in 57% of cases. Stents of 100mm and 80mm were implanted in 67% and 33% of cases respectively, using Gemini balloons. Additional stents were implanted at the upper part in 3 patients (10%). An ostium secundum atrial septal defect was closed during the same procedure in 2 patients (6.7%). No stent embolization, pulmonary vein compression, significant residual shunt or tamponade were observed. No peri-procedural death was reported during the follow-up. In one patient, a moderate pericardial effusion was observed 7 days after the procedure and resolved spontaneously. A flat thrombus of 4x22mm was fortuitously observed upholstering the bottom part of the covered stent on the systematic computed tomography scan control at 6 months. No other stent related adverse event. Transcatheter SVDs correction using OPTIMUS XXL® covered stents is safe and effective with excellent early and mid-term outcomes.
{"title":"Transcatheter correction of superior sinus venosus defects: early and mid-term results in a prospective, nationwide, multi-center study","authors":"G Albenque, C Batteux, C Karsenty, I Bouzguenda, P Aldebert, J Radojevic, G Bosser, B Lefort, P Moceri, R N Haddad, H Bouvaist, N Combes, A Houeijeh, V Ciobotaru, S Hascoet","doi":"10.1093/eurheartj/ehaf784.2813","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf784.2813","url":null,"abstract":"Transcatheter correction has been a new innovative treatment for superior sinus venosus defects (SVDs). A dedicated long partially covered XXL stent has been developed specifically for this procedure. Its safety and efficacy have to be investigated. This study aims to evaluate the efficacy and safety of transcatheter SVDs correction with the OTIMUS XXL® partially covered stent. A prospective, nationwide, multi-center cohort study with approval to include 60 consecutive patients started in June 2023. Preliminary early and mid-term (6 months) outcomes were collected. Results: Thirty adults were enrolled over one year in 5 centers (mean age 61 years; female, 73%; dyspnea, 90%; history of atrial arrhythmia, 43%; pulmonary hypertension, 40%; heart failure, 47%; mean indexed right ventricular end-telediastolic volume= 140mL/m² on MRI). Simulation of transcatheter SVD closure was done virtually and on 3D printed models in all cases. All procedures were successful. Pulmonary vein pathway was protected in 57% of cases. Stents of 100mm and 80mm were implanted in 67% and 33% of cases respectively, using Gemini balloons. Additional stents were implanted at the upper part in 3 patients (10%). An ostium secundum atrial septal defect was closed during the same procedure in 2 patients (6.7%). No stent embolization, pulmonary vein compression, significant residual shunt or tamponade were observed. No peri-procedural death was reported during the follow-up. In one patient, a moderate pericardial effusion was observed 7 days after the procedure and resolved spontaneously. A flat thrombus of 4x22mm was fortuitously observed upholstering the bottom part of the covered stent on the systematic computed tomography scan control at 6 months. No other stent related adverse event. Transcatheter SVDs correction using OPTIMUS XXL® covered stents is safe and effective with excellent early and mid-term outcomes.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"71 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2026-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146210415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-18DOI: 10.1093/eurheartj/ehaf784.4838
S Fathieh, V B Abdul-Salam, J Shalhoub, D R J Owen, M R Wilkins, R J Edwards, P Ramrakha
Background Atherosclerotic cardiovascular disease (CVD) remains the leading cause of global mortality, necessitating robust biomarkers for improved risk stratification and early intervention. Plasma lysozyme has demonstrated excellent diagnostic accuracy for CAD. However, its prognostic significance in long-term mortality remains unexplored. This study investigates the association between baseline arterial lysozyme concentration and all-cause mortality in a well-characterised cohort, evaluating its potential as a predictive biomarker for adverse outcomes in CAD. Methods We performed a long-term follow-up of a previously established cohort of 399 patients who underwent coronary angiography. Arterial lysozyme concentrations were measured via enzyme-linked immunosorbent assay (ELISA), with clinical and demographic data recorded at baseline. The primary endpoint was all-cause mortality, determined through linkage with national death registries and hospital records. Survival analysis was conducted using Kaplan-Meier curves. Cox proportional hazards regression models were employed to assess the independent association of lysozyme with mortality, adjusting for key confounders including age, sex, comorbidities, and traditional cardiovascular risk factors. A data-driven threshold of 1.5 was identified as the optimal cut-off for defining high-risk individuals. Results Over a median follow-up of 16 years (IQR: 15–20), elevated arterial lysozyme concentration was significantly associated with increased mortality risk in both univariate (HR = 1.06, 95% CI: 1.03–1.08, p < 0.001) and multivariate analysis (HR = 1.10, 95% CI: 1.04–1.15, p < 0.001). Stratification using the 1.5 threshold demonstrated high sensitivity (86.9%) and specificity (87.3%) for CAD risk. Patients in the high lysozyme group had a significantly increased mortality hazard (univariate HR = 2.42, 95% CI: 1.63–3.60, p < 0.001; multivariate HR = 2.07, 95% CI: 1.23–3.50, p = 0.006). Kaplan-Meier survival analysis (Figure 1) further confirmed a markedly reduced survival probability in the high lysozyme group (p < 0.0001), reinforcing its prognostic significance. Conclusion Elevated arterial lysozyme concentration is a powerful and independent predictor of long-term mortality in patients undergoing coronary angiography. The identified threshold of 1.5 effectively stratifies high-risk individuals, demonstrating strong predictive value beyond traditional cardiovascular risk factors. These findings position arterial lysozyme as a promising biomarker for risk assessment in atherosclerosis, warranting further investigation into its mechanistic role and potential integration into clinical decision-making to enhance early intervention and patient outcomes.
背景：动脉粥样硬化性心血管疾病（CVD）仍然是全球死亡的主要原因，需要强有力的生物标志物来改善风险分层和早期干预。血浆溶菌酶对CAD的诊断具有很高的准确性。然而，其在长期死亡率中的预后意义仍未被探索。本研究在一个特征明确的队列中调查了基线动脉溶菌酶浓度与全因死亡率之间的关系，评估了其作为CAD不良结局预测生物标志物的潜力。方法我们对先前建立的399例接受冠状动脉造影的患者进行了长期随访。通过酶联免疫吸附试验（ELISA）测量动脉溶菌酶浓度，并在基线记录临床和人口统计学数据。主要终点是全因死亡率，通过与国家死亡登记和医院记录的联系确定。采用Kaplan-Meier曲线进行生存分析。采用Cox比例风险回归模型评估溶菌酶与死亡率的独立相关性，并对年龄、性别、合并症和传统心血管危险因素等关键混杂因素进行调整。数据驱动的阈值1.5被确定为定义高风险个体的最佳截止值。结果中位随访16年（IQR: 15-20），在单因素分析（HR = 1.06, 95% CI: 1.03-1.08, p < 0.001）和多因素分析（HR = 1.10, 95% CI: 1.04-1.15, p < 0.001）中，动脉溶菌酶浓度升高与死亡风险增加显著相关。使用1.5阈值分层显示CAD风险的高敏感性（86.9%）和特异性（87.3%）。高溶菌酶组患者死亡风险显著增加（单因素HR = 2.42, 95% CI: 1.63-3.60, p < 0.001；多因素HR = 2.07, 95% CI: 1.23-3.50, p = 0.006）。Kaplan-Meier生存分析（图1）进一步证实了高溶菌酶组的生存率显著降低（p < 0.0001），加强了其预后意义。结论动脉溶菌酶浓度升高是冠状动脉造影患者长期死亡率的独立预测指标。所确定的阈值1.5有效地对高危人群进行分层，显示出超越传统心血管危险因素的强大预测价值。这些发现将动脉溶菌酶定位为动脉粥样硬化风险评估的有前景的生物标志物，值得进一步研究其机制作用和潜在的临床决策整合，以提高早期干预和患者预后。
{"title":"Examining the predictive value of plasma lysozyme for future all-cause mortality","authors":"S Fathieh, V B Abdul-Salam, J Shalhoub, D R J Owen, M R Wilkins, R J Edwards, P Ramrakha","doi":"10.1093/eurheartj/ehaf784.4838","DOIUrl":"https://doi.org/10.1093/eurheartj/ehaf784.4838","url":null,"abstract":"Background Atherosclerotic cardiovascular disease (CVD) remains the leading cause of global mortality, necessitating robust biomarkers for improved risk stratification and early intervention. Plasma lysozyme has demonstrated excellent diagnostic accuracy for CAD. However, its prognostic significance in long-term mortality remains unexplored. This study investigates the association between baseline arterial lysozyme concentration and all-cause mortality in a well-characterised cohort, evaluating its potential as a predictive biomarker for adverse outcomes in CAD. Methods We performed a long-term follow-up of a previously established cohort of 399 patients who underwent coronary angiography. Arterial lysozyme concentrations were measured via enzyme-linked immunosorbent assay (ELISA), with clinical and demographic data recorded at baseline. The primary endpoint was all-cause mortality, determined through linkage with national death registries and hospital records. Survival analysis was conducted using Kaplan-Meier curves. Cox proportional hazards regression models were employed to assess the independent association of lysozyme with mortality, adjusting for key confounders including age, sex, comorbidities, and traditional cardiovascular risk factors. A data-driven threshold of 1.5 was identified as the optimal cut-off for defining high-risk individuals. Results Over a median follow-up of 16 years (IQR: 15–20), elevated arterial lysozyme concentration was significantly associated with increased mortality risk in both univariate (HR = 1.06, 95% CI: 1.03–1.08, p &lt; 0.001) and multivariate analysis (HR = 1.10, 95% CI: 1.04–1.15, p &lt; 0.001). Stratification using the 1.5 threshold demonstrated high sensitivity (86.9%) and specificity (87.3%) for CAD risk. Patients in the high lysozyme group had a significantly increased mortality hazard (univariate HR = 2.42, 95% CI: 1.63–3.60, p &lt; 0.001; multivariate HR = 2.07, 95% CI: 1.23–3.50, p = 0.006). Kaplan-Meier survival analysis (Figure 1) further confirmed a markedly reduced survival probability in the high lysozyme group (p &lt; 0.0001), reinforcing its prognostic significance. Conclusion Elevated arterial lysozyme concentration is a powerful and independent predictor of long-term mortality in patients undergoing coronary angiography. The identified threshold of 1.5 effectively stratifies high-risk individuals, demonstrating strong predictive value beyond traditional cardiovascular risk factors. These findings position arterial lysozyme as a promising biomarker for risk assessment in atherosclerosis, warranting further investigation into its mechanistic role and potential integration into clinical decision-making to enhance early intervention and patient outcomes.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"8 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2026-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146210489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-18DOI: 10.1093/eurheartj/ehag108
Filippo Crea
{"title":"Novel insight into congenital heart disease from large international registries.","authors":"Filippo Crea","doi":"10.1093/eurheartj/ehag108","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag108","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"47 7","pages":"779-783"},"PeriodicalIF":35.6,"publicationDate":"2026-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-18DOI: 10.1093/eurheartj/ehag074
Gerard Pasterkamp, Minna U Kaikkonen, Michal Mokry
{"title":"Spatial mapping of stability in human atherosclerosis for the next generation of patient stratification.","authors":"Gerard Pasterkamp, Minna U Kaikkonen, Michal Mokry","doi":"10.1093/eurheartj/ehag074","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag074","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":35.6,"publicationDate":"2026-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146219216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：